TAK 659

Drug Profile

TAK 659

Alternative Names: TAK-659

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium
  • Developer Takeda Oncology
  • Class Antineoplastics
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Breast cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 01 Aug 2017 Phase-I clinical trials in Diffuse large B cell lymphoma (Monotherapy, Second-line therapy or greater) in Japan (PO) (NCT03238651)
  • 01 Aug 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Monotherapy) in Japan (PO) (NCT03238651)
  • 24 Apr 2017 Millennium Pharmaceuticals plans a phase II trial for Diffuse large B-cell lymphoma (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in France, Italy, Spain, United Kingdom and USA (NCT03123393)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top